Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава Росси
发明人:
Троянов Алексей Владимирович (RU),Карякин Олег Борисович (RU),Бирюков Виталий Александрович (RU),Гуменецкая Юлия Васильевна (RU)
申请号：
RU2019127438
公开号：
RU2019127438A
申请日:
2019.08.30
申请国别(地区):
RU
年份:
2019
代理人:
摘要：
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely oncourology, and can be used for complex hormone-chemoradiation treatment of localized or locally advanced prostate cancer (PC) of high and very high risk of progression. Neoadjuvant hormone chemotherapy is prescribed by docetaxel in dose of 75 mg/mintravenously once every 21 days, total 4 injections, and a hormonal preparation Degarelix 240 mg subcutaneously – starting dose, then every 28 days in a maintenance dose of 80 mg. After 4 courses of neoadjuvant hormone chemotherapy, combined radiation therapy is performed: 22-23 sessions 2 Gy to total radiation dose 44–46 Gy – remote radiation therapy, and in 2–3 weeks – high-power interstitial radiation therapy (brachytherapy) Ir– single radiation dose 15 Gy, further hormonal therapy is continued to total duration of 24 months.EFFECT: method provides higher clinical effectiveness ensured by combined radiation therapy combined with hormone-chemoradiation treatment.1 cl, 2 ex
